Adrenal Cortex Neoplasms
📧 Sign up to get email alerts when something new happens for Adrenal Cortex Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-11EMA Authorised: Lysodren (mitotane) — Esteve Pharmaceuticals, S.A.
EMA authorised marketing of Lysodren (mitotane) by Esteve Pharmaceuticals, S.A. for adrenal cortex neoplasms.
-
CLINICAL_TRIALS trial_result · 2013-06-27Clinical Trial Update: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer [Phase 2]
Phase II study of Axitinib (AG-013736) evaluating the VEGF pathway in metastatic, recurrent, or unresectable adrenocortical cancer has compl…
-
CLINICAL_TRIALS trial_result · 2008-10-08Clinical Trial Update: Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma
This is a completed clinical trial evaluating cardiovascular risk in patients with non-functional adrenal incidentaloma.